Alaunos Therapeutics (NASDAQ:TCRT) Shares Up 20.6% – Still a Buy?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares shot up 20.6% on Wednesday . The stock traded as high as $2.88 and last traded at $2.81. 51,176 shares changed hands during mid-day trading, an increase of 206% from the average session volume of 16,703 shares. The stock had previously closed at $2.33.

Alaunos Therapeutics Trading Up 20.6 %

The business’s 50-day moving average price is $2.44 and its two-hundred day moving average price is $4.77.

Institutional Trading of Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned 0.10% of Alaunos Therapeutics at the end of the most recent reporting period. Institutional investors own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.